The four options at a glance
All four are daily injections your doctor may consider for recovery. The main difference is what's in the cartridge.
| Product | Contains | Usually considered for |
|---|---|---|
| BPC-157 Cartridge | BPC-157 14 mg in 2,4 ml | Localised soft-tissue injury and gut-lining support |
| TB-500 Cartridge | TB-500 14 mg in 2,4 ml | Connective-tissue repair and flexibility after injury |
| Wolverine Stack Cartridge | BPC-157 14 mg and TB-500 14 mg in 2,6 ml | Stubborn tendon, ligament and muscle injuries |
| Glow Stack Cartridge | BPC-157 14 mg, TB-500 14 mg and GHK-Cu 70 mg in 2,4 ml | Repair and skin-quality goals together |
What BPC-157 is
BPC-157 is a synthetic chain of 15 amino acids. Laboratory and animal research has looked at blood-vessel growth, collagen production and repair of tendon, ligament and gut tissue.
The human evidence is very limited. A 2025 systematic review found one published human study: 12 people with chronic knee pain, 7 of whom reported improvement. That study was retrospective, had no comparison group and used injections into the joint.
The same review said human safety remains unknown. It concluded that the findings can't yet support clinical guidelines.
What TB-500 is
TB-500 is often described as thymosin beta-4, but they aren't the same thing. Laboratory analysis of TB-500 identified a seven-amino-acid fragment of thymosin beta-4, called Ac-LKKTETQ.
This matters when reading the research. A small placebo-controlled study of about 40 healthy volunteers found intravenous thymosin beta-4 was well tolerated for up to 14 days. That study tested the full molecule, by a different route, and didn't look at injury recovery.
Human evidence for the TB-500 fragment itself is even more limited, so results for thymosin beta-4 can't simply be assumed to apply.
Why they're combined
Researchers think BPC-157 and TB-500 act on different parts of healing: BPC-157 on blood vessels and collagen, TB-500 on how cells move to injured tissue. This is the reasoning behind the Wolverine Stack.
It's a rationale, not proof. We didn't find human trials showing the combination works better than either one alone, or better than rehabilitation.
What Glow adds
Glow adds GHK-Cu, a copper-binding compound studied mainly for skin. Most human skin studies used creams or serums, not injections. For more detail, read our GHK-Cu guide.
Glow isn't suitable for people with Wilson's disease or another copper-handling disorder. Tell your doctor if you take copper supplements or a multivitamin containing copper.
How your doctor may choose
These questions can help you prepare for your consultation:
- Is your main goal injury recovery, skin quality or both?
- Has your injury been properly diagnosed, including with a scan if needed?
- Have you completed physiotherapy or a structured rehabilitation plan?
- Do you need more than one compound, or would fewer be simpler?
Fewer ingredients also make it easier to work out what caused any reaction.
Safety points
Ambrosia's product information lists these reasons not to use BPC-157, TB-500 or the stacks:
- Active cancer or a history of cancer
- Pregnancy or breastfeeding
- Hypersensitivity to any ingredient
Tell your doctor if you take blood thinners, antiplatelets or growth-promoting treatments. Possible side effects include injection-site redness or bruising, nausea, dizziness, headache and fatigue.
BPC-157 and TB-500 are on the World Anti-Doping Agency's Prohibited List and are banned in and out of competition. Don't use them if you compete under an anti-doping code.
Every Ambrosia treatment requires a prescription from a doctor who has reviewed your medical history.
This article is for educational purposes only and is not medical advice.
References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal, 2012
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 2010
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018
- World Anti-Doping Agency: 2026 Prohibited List


